Last reviewed · How we verify

blind injection of Triamcinolone

Complejo Hospitalario Universitario de Granada · FDA-approved active Small molecule

Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.

Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. Used for Intra-articular injection for inflammatory joint conditions and arthritis, Periarticular injection for soft tissue inflammation and pain.

At a glance

Generic nameblind injection of Triamcinolone
Also known asBlind introduction of Triamcinolone
SponsorComplejo Hospitalario Universitario de Granada
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRheumatology / Orthopedics / Immunology
PhaseFDA-approved

Mechanism of action

Triamcinolone exerts its anti-inflammatory effects by translocating to the nucleus and modulating gene expression of pro-inflammatory cytokines, adhesion molecules, and immune mediators. When administered via blind injection (typically intra-articular or periarticular), it provides localized immunosuppression and reduces inflammation at the injection site, with systemic absorption being minimal.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results